HomeCompareORXOF vs ORCC

ORXOF vs ORCC: Dividend Comparison 2026

ORXOF yields 87.48% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORXOF wins by $2.28M in total portfolio value
10 years
ORXOF
ORXOF
● Live price
87.48%
Share price
$2.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.30M
Annual income
$708,964.09
Full ORXOF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — ORXOF vs ORCC

📍 ORXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOF
Annual income on $10K today (after 15% tax)
$7,435.92/yr
After 10yr DRIP, annual income (after tax)
$602,619.48/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, ORXOF beats the other by $602,618.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOF + ORCC for your $10,000?

ORXOF: 50%ORCC: 50%
100% ORCC50/50100% ORXOF
Portfolio after 10yr
$1.16M
Annual income
$354,482.57/yr
Blended yield
30.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

ORXOF
No analyst data
Altman Z
-0.2
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOF buys
0
ORCC buys
18
PoliticianChamberTickerTypeAmountDate
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-23
Trey Hollingsworth🏢 House$ORCC▲ Buy$250,001 - $500,0002022-06-16
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-14
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-13
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-10
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-09
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-08
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-03
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-05-24
Trey Hollingsworth🏢 House$ORCC▲ Buy$100,001 - $250,0002022-05-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOFORCC
Forward yield87.48%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$2.30M$21.4K
Annual income after 10y$708,964.09$1.04
Total dividends collected$2.02M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ORXOF vs ORCC ($10,000, DRIP)

YearORXOF PortfolioORXOF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$19,448$8,748.14$11,190$489.61+$8.3KORXOF
2$36,710$15,900.47$12,229$256.01+$24.5KORXOF
3$67,330$28,049.97$13,216$130.74+$54.1KORXOF
4$120,123$48,080.71$14,207$66.02+$105.9KORXOF
5$208,701$80,169.36$15,234$33.17+$193.5KORXOF
6$353,484$130,173.43$16,317$16.62+$337.2KORXOF
7$584,283$206,054.85$17,468$8.32+$566.8KORXOF
8$943,494$318,311.52$18,695$4.16+$924.8KORXOF
9$1,489,918$480,379.75$20,006$2.08+$1.47MORXOF
10$2,303,177$708,964.09$21,407$1.04+$2.28MORXOF

ORXOF vs ORCC: Complete Analysis 2026

ORXOFStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this ORXOF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOF vs SCHDORXOF vs JEPIORXOF vs OORXOF vs KOORXOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.